Literature DB >> 26261678

Endometrial tubal metaplasia in a young puerperal woman after breast cancer.

Luisa Di Benedetto1, Valentina Giovanale1, Donatella Caserta1.   

Abstract

INTRODUCTION: Tamoxifen is the usual endocrine (anti-estrogen) therapy for hormone receptor-positive breast cancer in pre and post-menopausal women. Previous studies have suggested an increased prevalence of endometrial diseases after treatment with tamoxifen. CASE
PRESENTATION: The authors report a case of 38-year-old woman with diagnosis of endometrial polyp and tubal metaplasia, during puerperium and after micropapillary ductal breast cancer surgery, 5 years of tamoxifen treatment, spontaneous pregnancy without complications and full-term vaginal delivery.
CONCLUSION: Tamoxifen is a safe and reliable treatment of breast cancer, but data suggest an association with endometrial polyps, hyperplasia, metaplasia and carcinoma. One of the most common types of endometrial metaplasia is ciliated tubal metaplasia. It is generally known that endometrial tubal metaplasia is a benign disease. However studies propose endometrial tubal metaplasia to be a potential premalignant endometrial lesion and its association with endometrial hyperplasia and well-differentiated endometrioid carcinoma. We propose close monitoring of patients taking tamoxifen and prompt evaluation of any uterine bleeding or pelvic complaint or abnormal TVUS images.

Entities:  

Keywords:  Breast cancer; endometrial polyp; tamoxifen; tubal metaplasia

Mesh:

Substances:

Year:  2015        PMID: 26261678      PMCID: PMC4526012     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  13 in total

Review 1.  Antagonistic and agonistic effects of tamoxifen: significance in human cancer.

Authors:  M A Gallo; D Kaufman
Journal:  Semin Oncol       Date:  1997-02       Impact factor: 4.929

2.  Tubal metaplasia of the endometrium with cytologic atypia: analysis of p53, Ki-67, TERT, and long-term follow-up.

Authors:  Rochelle A Simon; Shu-Ling Peng; Fang Liu; M Ruhul Quddus; Cunxian Zhang; Margaret M Steinhoff; W Dwayne Lawrence; C James Sung
Journal:  Mod Pathol       Date:  2011-05-13       Impact factor: 7.842

Review 3.  Endometrial metaplasias and reactive changes: a spectrum of altered differentiation.

Authors:  Alina Nicolae; Ovidiu Preda; Francisco F Nogales
Journal:  J Clin Pathol       Date:  2010-12-01       Impact factor: 3.411

4.  Endometrial cartilaginous metaplasia: A case report with literature review.

Authors:  Sunita B Patil; Shilpa Narchal; Seema S More
Journal:  J Midlife Health       Date:  2013-07

5.  Risk factors for young premenopausal women with endometrial cancer.

Authors:  Pamela T Soliman; Jonathan C Oh; Kathleen M Schmeler; Charlotte C Sun; Brian M Slomovitz; David M Gershenson; Thomas W Burke; Karen H Lu
Journal:  Obstet Gynecol       Date:  2005-03       Impact factor: 7.661

Review 6.  Tamoxifen (TAM): the dispute goes on.

Authors:  Sandro Grilli
Journal:  Ann Ist Super Sanita       Date:  2006       Impact factor: 1.663

7.  Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen.

Authors:  L Bergman; M L Beelen; M P Gallee; H Hollema; J Benraadt; F E van Leeuwen
Journal:  Lancet       Date:  2000-09-09       Impact factor: 79.321

8.  Tumorigenic effects of tamoxifen on the female genital tract.

Authors:  Kaei Nasu; Noriyuki Takai; Masakazu Nishida; Hisashi Narahara
Journal:  Clin Med Pathol       Date:  2008-03-01

9.  Endometrial pathology in breast cancer patients: Effect of different treatments on ultrasonographic, hysteroscopic and histological findings.

Authors:  Maria LE Donne; Angela Alibrandi; Leonarda Ciancimino; Andrea Azzerboni; Benito Chiofalo; Onofrio Triolo
Journal:  Oncol Lett       Date:  2013-01-28       Impact factor: 2.967

10.  p16 is consistently expressed in endometrial tubal metaplasia.

Authors:  N Horree; A P M Heintz; D M D S Sie-Go; P J van Diest
Journal:  Cell Oncol       Date:  2007       Impact factor: 6.730

View more
  3 in total

1.  Synergism between PGC-1α and estrogen in the survival of endometrial cancer cells via the mitochondrial pathway.

Authors:  Hui Yang; Rui Yang; Hao Liu; Zhongqian Ren; Fanfei Kong; Da Li; Xiaoxin Ma
Journal:  Onco Targets Ther       Date:  2016-06-30       Impact factor: 4.147

2.  "Best practices in risk reducing bilateral salpingo-oophorectomy: the influence of surgical specialty".

Authors:  Dominique R Malacarne; Leslie R Boyd; Yang Long; Stephanie V Blank
Journal:  World J Surg Oncol       Date:  2017-12-11       Impact factor: 2.754

3.  Could Obesity be a Triggering Factor for Endometrial Tubal Metaplasia to be a Precancerous Lesion?

Authors:  Ayman M El-Saka; Yomna A Zamzam; Yosra A Zamzam; Ayman El-Dorf
Journal:  J Obes       Date:  2020-03-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.